|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
140,280,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,724,137 |
1,724,327 |
1,724,327 |
1,724,327 |
Total Buy Value |
$4,999,997 |
$5,000,680 |
$5,000,680 |
$5,000,680 |
Total People Bought |
1 |
2 |
2 |
2 |
Total Buy Transactions |
1 |
2 |
2 |
2 |
Total Shares Sold |
0 |
18,640 |
28,640 |
71,242 |
Total Sell Value |
$0 |
$50,317 |
$93,172 |
$615,058 |
Total People Sold |
0 |
1 |
2 |
5 |
Total Sell Transactions |
0 |
1 |
2 |
11 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Belldegrun Arie |
|
|
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
53,635 |
203,968 |
|
- |
|
Chang David D |
President and CEO |
|
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
80,452 |
2,284,869 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
22,202 |
421,353 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2021-03-15 |
4 |
S |
$38.14 |
$235,089 |
D/D |
(6,164) |
102,574 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2021-03-15 |
4 |
S |
$38.23 |
$307,889 |
D/D |
(8,053) |
71,231 |
|
- |
|
Chang David D |
President and CEO |
|
2021-03-15 |
4 |
S |
$38.57 |
$791,271 |
D/D |
(20,513) |
2,204,417 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2021-03-15 |
4 |
AS |
$37.79 |
$630,798 |
D/D |
(16,623) |
399,151 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2021-03-15 |
4 |
OE |
$2.27 |
$22,700 |
D/D |
10,000 |
415,774 |
|
- |
|
Amado Rafael |
EVP of R&D and CMO |
|
2021-03-15 |
4 |
S |
$38.05 |
$106,471 |
D/D |
(2,798) |
110,035 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2021-01-15 |
4 |
AS |
$31.69 |
$483,859 |
I/I |
(15,000) |
1,152,595 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2021-01-14 |
4 |
AS |
$30.60 |
$461,610 |
I/I |
(15,000) |
1,167,595 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-12-17 |
4 |
OE |
$2.27 |
$116,905 |
D/D |
51,500 |
405,402 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2020-11-16 |
4 |
AS |
$32.60 |
$493,146 |
I/I |
(15,000) |
1,182,595 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2020-10-15 |
4 |
AS |
$39.47 |
$607,392 |
I/I |
(15,000) |
1,197,595 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-13 |
4 |
AS |
$42.00 |
$463,302 |
D/D |
(11,031) |
108,370 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-13 |
4 |
OE |
$2.27 |
$25,040 |
D/D |
11,031 |
119,401 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-12 |
4 |
AS |
$42.00 |
$1,017,786 |
D/D |
(24,233) |
108,370 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-12 |
4 |
OE |
$2.27 |
$55,009 |
D/D |
24,233 |
132,603 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-09 |
4 |
AS |
$41.00 |
$1,619,869 |
D/D |
(39,509) |
108,370 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-09 |
4 |
OE |
$2.27 |
$68,552 |
D/D |
30,199 |
147,879 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-08 |
4 |
AS |
$41.00 |
$207,665 |
D/D |
(5,065) |
117,680 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-08 |
4 |
OE |
$2.27 |
$11,498 |
D/D |
5,065 |
122,745 |
|
- |
|
Amado Rafael |
EVP of R&D and CMO |
|
2020-10-07 |
4 |
AS |
$39.40 |
$651,515 |
D/D |
(16,538) |
111,677 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-06 |
4 |
AS |
$40.00 |
$1,782,960 |
D/D |
(44,574) |
117,680 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-10-06 |
4 |
OE |
$2.27 |
$80,049 |
D/D |
35,264 |
161,536 |
|
- |
|
225 Records found
|
|
Page 5 of 9 |
|
|